Skip to content

LISA vs INSURE in the Treatment of Respiratory Distress Syndrome in Preterm Infants

The Efficacy of LISA Technology With Noninvasive Ventilation in the Treatment of Respiratory Distress Syndrome in Preterm Neonates

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04126382
Enrollment
200
Registered
2019-10-15
Start date
2020-01-01
Completion date
2024-12-31
Last updated
2019-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Infants

Keywords

NRDS, preterm infants, LISA, INSURE

Brief summary

To evaluate the efficacy of less invasive surfactant administration(LISA )technique in the treatment of neonatal respiratory distress syndrome(NRDS) by comparing with the traditional Intubate-Surfactant-Extubate(INSURE) technique.

Detailed description

Background: Neonatal Respiratory distress syndrome (NRDS) is the most common cause of respiratory problems in premature babies. Surfactant administration involved with endotracheal intubation and mechanical ventilation has proven to be a effective treatment, however, it is associated with a risk of barotrauma, volutrauma and bronchopulmonary dysplasia(BPD). In recent years, some studies have demonstrated that prophylactic INSURE did not lead to a higher survival without BPD, and LISA technique is recommended. However there is no multicenter and Large sample research about it. The aim of this multicenter trial is to compare the efficacy between LISA-treated and INSURE-treated premature Preterm babies with respiratory distress syndrome(RDS). Methods/Design:In this multicenter, randomized, cohort, prospective trial, 200 preterm infants from 18 neonatal intensive care units in AnHui province whose gestational age (GA) less than 32 weeks with a diagnosis of RDS will be randomized to LISA-treated group and INSURE-treated group. The primary outcomes include rate of intubation,incidence of bronchopulmonary dysplasia(BPD).The secondary outcomes include arterial blood gas analysis,severity of RDS,the incidence of Patent ductus arteriosus(PDA),Pneumothorax,Abdominal Distention,Neonatal Necrotizing Enterocolitis(NEC,\>Stage II), Retinopathy of Prematurity( ROP,≥ Stage II), Intraventricular Hemorrhage (IVH, ≥ Grade Ⅲ), Periventricular Leukomalacia(PVL) , mortality, days on noninvasive respiratory support,days on supplemental oxygen and days of hospitalization.Other secondary outcomes include scores of Gesell development Scales of infant development at 3 years of corrected age.

Interventions

PROCEDUREIntubate-Surfactant-Extubate(INSURE)

Infants are given an endotracheal intubation, with manual lung inflation in order to keep the oxygen supply,and the surfactant(kelisu,China Resources Shuanghe Pharmaceutical) was slowly instilled into the airway through the tracheal tube, and the tracheal tube was removed for non-invasive NCPAP(nasal continuous positive airway pressure)-assisted breathing.

PROCEDUREless invasive surfactant administration(LISA)

Infants are spontaneously breathing with nasal CPAP(continuous positive airway pressure) support without manual lung inflation and surfactant(kelisu,China Resources Shuanghe Pharmaceutical) is administered through vocal cords via a smaller catheter.

Sponsors

The First Affiliated Hospital of University of Science and Technology of China
CollaboratorOTHER
The First Affiliated Hospital of Bengbu Medical University
CollaboratorOTHER
Second Affiliated Hospital of Bengbu Medical College
CollaboratorOTHER
Fuyang people's hospital
CollaboratorOTHER
lixin people's hospital
CollaboratorUNKNOWN
The Third People's Hospital of Bengbu
CollaboratorOTHER_GOV
Huaibei coal general hospital
CollaboratorUNKNOWN
Bozhou people's hospital
CollaboratorUNKNOWN
Luan people's hospital
CollaboratorUNKNOWN
Huaibei maternal and child health hospital
CollaboratorUNKNOWN
Huainan maternal and child health hospital
CollaboratorUNKNOWN
Chizhou people's hospital
CollaboratorUNKNOWN
Xuancheng people's hospital
CollaboratorUNKNOWN
First Affiliated Hospital of Wannan Medical College
CollaboratorOTHER
Tongling People's Hospital
CollaboratorOTHER_GOV
Maanshan maternity and child care
CollaboratorUNKNOWN
Wuhu first people's hospital
CollaboratorUNKNOWN
Anqing Municipal Hospital
CollaboratorOTHER
Anhui Provincial Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
25 Weeks to 32 Weeks
Healthy volunteers
No

Inclusion criteria

* Gestational age (GA) less than 32 weeks * diagnosis of RDS. The diagnosis of RDS will be based on clinical manifestations (Progressive dyspnea, nasal flaring and or grunting), chest X-ray findings and need for noninvasive ventilation support(fraction of inspired oxygen\>40%) in 6 hours after birth * informed parental consent has been obtained

Exclusion criteria

* severe RDS have been treated with endotracheal intubation,surfactant and mechanical ventilation * major congenital malformations or complex congenital heart disease * Pulmonary hemorrhage * Cardiopulmonary failure * septicemia, Intraventricular Hemorrhage (IVH, ≥ Grade Ⅲ), and Congenital genetic metabolic disease * transferred out of the NICUs(neonatal intensive care units) with surgical treatment or other intervention

Design outcomes

Primary

MeasureTime frameDescription
Rate of intubationduring the first 3 days after birthThe criteria for endotracheal mechanical ventilation were as follows: severe apnea and bradycardia (defined as recurrent apnea with \> 3 episodes per hour associated with heart rate \< 100/min, a single episode of apnea that required bag and mask ventilation), hypoxia (FiO2\>0.6 with PaO2\<50mmHg or TcSO\<0.85), severe respiratory acidosis (PaCO2 \> 60 mmHg with pH\<7.20).
The incidence of bronchopulmonary dysplasiaat a post-menstrual age of 36 weeks or at dischargeBPD was diagnosed and classified based on the Practical neonatology 4th edition:Need for O2 supplementation(FiO2\>0.21) for at least 28 days after birth.

Secondary

MeasureTime frameDescription
The Incidence of Pneumothoraxduring non-invasive ventilation, up to 30 daysPneumothorax was diagnosed based on clinical manifestations and features of chest x-ray
The Incidence of Abdominal Distentionduring non-invasive ventilation, up to 30 daysAbdominal circumference was measured 3 times a day during non-invasive ventilation
The Incidence of Neonatal Necrotizing Enterocolitis(>Stage II)during hospitalization, up to 60 daysNeonatal Necrotizing Enterocolitis was diagnosed by clinical manifestations and features of abdominal x-Ray based on the Practical neonatology 4th edition
The Incidence of Retinopathy of Prematurity( ≥ Stage II)at a post-menstrual age of 36 weeks or at dischargeThe criteria for Retinopathy of prematurity (\>Stage II); extraretinal fibrovascular proliferation neovascularization extends from ridge into the vitreous.
The Incidence of Intraventricular Hemorrhage (IVH, ≥ Grade Ⅲ)during hospitalization, up to 60 daysThe criteria for intraventricular hemorrhage (IVH, ≥ grade Ⅲ): intraventricular hemorrhage with ventricular dilatation and intraventricular hemorrhage with paren-ehymal hemorrhage.
Effect on of arterial blood gas analysisduring the whole procedure of surfactant replacement,up to 3 days after birthThe improvement of PaO2 and PaCO2 in two groups children with LISA technique
Predischarge Mortalityduring hospitalization, up to 60 days
The Time of Non-invasive Ventilationduring hospitalization, up to 60 daysHours
Days on supplemental oxygenduring hospitalization, up to 60 daysDays
Length of Hospitalizationduring hospitalization, up to 60 daysDays
The Incidence of Periventricular Leukomalaciaduring hospitalization, up to 36 monthsPeriventricular Leukomalacia was diagnosed based on cranial MRI
The Incidence of Patent ductus arteriosusduring hospitalization, up to 60 daysPDA was diagnosed based on echocardiography

Contacts

Primary ContactZhang Lan, PhD
moaana@163.com18256935186
Backup ContactPan Jiahua, PhD
panjiahua1960@163.com13866167758

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026